Complementary detection of genomic alterations in metastatic castration-resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.

被引：0
|
作者：
Sausen, Mark
Baden, Jonathan F.
Kalinava, Natallia
Wang, Xuya
Li, Jun
Anguiano, Esperanza
Unsal-Kacmaz, Keziban
Wind-Rotolo, Megan
Quinn, Katie
Green, George
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] Guardant Hlth Inc, Redwood City, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5038
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Wise, David
    Louw, Jessica
    Krupa, Rachel
    Schreiber, Nicole A.
    Sawyers, Charles L.
    Dittamore, Ryan Vance
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Genomic predictive and prognostic factors from plasma cell-free DNA (cfDNA) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) commencing enzalutamide (ENZ)
    Chi, K.
    Azad, A.
    Volik, S.
    Haegert, A.
    Le Bihan, S.
    McConeghy, B.
    Gleave, M.
    Wyatt, A.
    Collins, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S474 - S475
  • [43] Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Maurice-Dror, Corinne
    Fonseca, Nicolette
    Herberts, Cameron
    Fan, William
    Wyatt, Alexander W.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-na ve metastatic castration-resistant prostate cancer (mCRPC).
    Wyatt, Alexander William
    Annala, Matti
    Parimi, Sunil
    Zulfiqar, Muhammad
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Azad, Arun
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
    Conteduca, V.
    Scarpi, E.
    Wetterskog, D.
    Brighi, N.
    Schepisi, G.
    Romanel, A.
    Casadei, C.
    Lolli, C.
    Gurioli, G.
    Toma, I.
    Poti, G.
    Farolfi, A.
    Demichelis, F.
    Attard, G.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2021, 32 : S633 - S633
  • [46] Genomic alterations in plasma cell-free DNA predict treatment response to abiraterone acetate and prednisone and survival in metastatic castration-resistant prostate cancer
    Du, Meijun
    Kohli, Manish
    Huang, Chiang-Ching
    Wang, Liang
    CANCER RESEARCH, 2018, 78 (13)
  • [47] First and Second-line Therapy for metastatic castration-refractory Prostate Cancer (mCRPC) A Phase II Study of Nivolumab in combination with Rucaparib, Docetaxel or Enzalutamide in Men with castration-resistant metastatic Prostate Cancer (CheckMate-9KD) - AP 103/18 of AUO
    Rexer, H.
    Hammerer, P.
    Gruellich, C.
    UROLOGE, 2019, 58 (04): : 475 - 476
  • [48] Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients
    Fettke, Heidi
    Kwan, Edmond M.
    Yu, Jianjun
    Wang, Amy
    Montesinos, Carlos
    Wong, Calvin
    Gong, Xue
    Zheng, Tiantian
    Du, Peter Pan
    Jia, Shidong
    Mant, Andrew
    Parente, Phillip
    Pezaro, Carmel
    Azad, Arun A.
    CANCER RESEARCH, 2019, 79 (13)
  • [49] Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy
    Wyatt, A. W.
    Annala, M.
    Beja, K.
    Parimi, S.
    Vandekerkhove, G.
    Warner, E.
    Zulfiqar, M.
    Finch, D.
    Oja, C.
    Vergidis, J.
    Nykter, M.
    Gleave, M. E.
    Chi, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
    Sharma, Padmanee
    Pachynski, Russell Kent
    Narayan, Vivek
    Flechon, Aude
    Gravis, Gwenaelle
    Galsky, Matt D.
    Mahammedi, Hakim
    Patnaik, Akash
    Subudhi, Sumit Kumar
    Ciprotti, Marika
    Duan, Tao
    Saci, Abdel
    Hu, Sarah
    Han, G. Celine
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345